AAMP

Across TCGA pan-cancer cohorts, AAMP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AAMP data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AAMP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AAMP expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where AAMP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.568	0.910	<.001	20	view →
PDAC	DFS	Quartile	All	0.889	0.598	.003	20	view →
LUAD	DFS	Tertile	III,IV	0.924	0.371	<.001	17	view →
GBM	DFS	Median	All	0.244	0.486	.007	10	view →
HNSC	OS	Quartile	II,III,IV	0.687	0.910	.005	9	view →
UCEC	DFS	Tertile	All	0.855	0.985	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AAMP–CCRCC (DFS)

Open the CCRCC breakdown →